Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-05-07 Notice of Dividend Amou…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the implementation of the 2022 annual equity distribution plan, including details on stock dividends, cash dividends, tax implications, record dates, and share changes. It references the shareholders' meeting approval and provides specifics on dividend amounts and share issuance. The document is relatively short (2038 characters) and focuses on dividend distribution details rather than presenting a full annual report or financial statements. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related shareholder details.
2023-05-07 Chinese
董事长辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the chairman of the board of directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the resignation date, reasons, and the impact on the company and board composition. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. The content focuses solely on management change, specifically the chairman's resignation and interim arrangements. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS.
2023-04-26 Chinese
关于阿卡波糖片增加规格取得药品补充申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval of a supplementary drug application for an increased specification of a pharmaceutical product (Acarbose tablets). It includes details about the drug, regulatory approval, and risk warnings. The document is short (1216 characters) and serves as an official announcement of regulatory approval rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed investor information. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-25 Chinese
公司章程
Governance Information Classification · 95% confidence The document is titled as the Articles of Association (章程) of 江苏德源药业股份有限公司 (Jiangsu Deyuan Pharmaceutical Co., Ltd.). It contains detailed provisions about the company's general principles, business scope, shares issuance, shareholders and shareholders' meetings, board of directors, senior management, profit distribution, internal audit, appointment of auditors, information disclosure, and investor relations management. The content is focused on the company's governance structure, shareholder rights and obligations, board and management roles, and procedural rules for meetings and resolutions. This type of document is a governance document that sets out the internal rules and governance practices of the company. It is not a financial report, audit report, earnings release, or any announcement. It is a detailed governance information document, consistent with the category 'Governance Information' (CGR). The document length is substantial (15,000 characters), and it is the actual text of the articles, not an announcement or summary. Therefore, the correct classification is CGR with high confidence.
2023-04-20 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2022年年度股东大会之法律意见书
Regulatory Filings Classification · 95% confidence The document text is very short (3737 characters) and contains mostly garbled or non-standard characters, with some references to the year 2022 and 2023. There is no clear financial data, no detailed financial statements, no earnings highlights, no management discussion, no legal proceedings, no capital or financing updates, no voting results, no director dealings, no merger or acquisition information, no dividend announcements, and no clear presentation or transcript content. The text appears to be a partial or corrupted document, possibly a cover page or index page, with no substantive report content. It also mentions a website and contact information but no actual report or announcement content. Given the lack of substantive content and the short length, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2023-04-20 Chinese
关于变更注册资本通知债权人的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding changes in registered capital and notification to creditors. It details the board and shareholder meeting decisions about profit distribution, share repurchase and cancellation, and the resulting changes in registered capital. It also includes instructions for creditors to submit claims within a specified period. The document is a formal notice to creditors about capital changes and related legal rights, not a financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive content about the capital change and creditor notification. This fits the category of Share Issue/Capital Change (SHA) as it concerns changes in share capital and related corporate actions.
2023-04-20 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.